Search

• Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children

  Media

  Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate.

  https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-reduces-disease-over-18-months-of-follow-up-in-late-stage-study-of-more-than-15-000-infants-and-young-children/

  First published: 08 October 2013

• GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors

  Media

  GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-jonathan-symonds-as-non-executive-chairman-of-the-board-of-directors/

  First published: 24 July 2019

• GSK receives CHMP positive opinion recommending approval of dostarlimab for women with recurrent or advanced endometrial cancer

  Media

  This positive CHMP opinion brings us closer to providing dostarlimab as a new treatment option to women with endometrial cancer in Europe

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-recommending-approval-of-dostarlimab-for-women-with-recurrent-or-advanced-endometrial-cancer/

  First published: 26 February 2021

• ‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme

  Media

  Cases of meningitis B halved after ten months

  https://www.gsk.com/en-gb/media/press-releases/real-world-data-shows-83-percent-effectiveness-for-bexsero-in-infants-in-first-year-of-uk-national-meningitis-b-immunisation-programme/

  First published: 05 September 2016

• FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over

  Media

  The data supports the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over.

  https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-votes-unanimously-for-shingrix-hzsu-in-the-us-for-prevention-of-herpes-zoster-shingles-in-adults-ages-50-and-over/

  First published: 13 September 2017

• GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age

  Media

  GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/

  First published: 07 February 2018

• GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma

  Media

  GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma/

  First published: 21 May 2018

• GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK

  Media

  GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-programme-to-gsk/

  First published: 24 July 2018

• Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer

  Media

  TESARO announced the presentation of data from the Phase 1/2 GARNET study

  https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/

  First published: 19 March 2019

• GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development

  Media

  GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.

  https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development/

  First published: 27 January 2020